Merck (MRK) reported Q4 FY2022 earnings of $1.62 per share (versus $1.80 per share in Q4 FY2021), beating analysts’ consensus estimate of $1.54 per share.
The company’s quarterly revenues amounted to $13.830 bln (+2.3% y/y), beating analysts’ consensus estimate of $13.656 bln.
MRK fell to $104.65 (-2.18%) in pre-market trading.
